Curevac Vaccine Status Eu

Curevac Vaccine Status Eu. BRUSSELS Reuters - The European Union has struck a deal for up 405 million doses of German biotech firm CureVacs 5CVDE. CureVacs coronavirus vaccine only 47 percent effective German firm carried out study of 40000 people in 10 countries in Europe and Latin America with at least 13 coronavirus variants.

FRANKFURT Reuters -Curevac said it was in discussions with its prospective customer the European Union about where in the world to best deploy its experimental COVID-19 vaccine if it wins approval. The European Commission authorised the fourth COVID-19 vaccine in the EU COVID-19 Vaccine Janssen following evaluation by EMA. Curevac also has a separate agreement with German chemicals giant Bayer to make the vaccine from 2022.

EU vaccine approval still outstanding.

FRANKFURT May 5 Reuters - Germanys CureVac 5CVDE is on track to file for European approval of its COVID-19 vaccine as early as this month because high infection rates among trial. As CureVacs only major supply deal the European Union in November last year secured up to 405 million doses of the shot of which 180 million are optional. CureVacs coronavirus vaccine only 47 percent effective German firm carried out study of 40000 people in 10 countries in Europe and Latin America with at least 13 coronavirus variants. The vaccine should only be available to the population once its safety and efficacy will have been cleared by the competent regulatory bodies.